Results 121 to 130 of about 222,862 (245)

Investigations into the characterization, degradation, and applications of biodegradable polymers by mass spectrometry

Mass Spectrometry Reviews, EarlyView., 2023
Abstract Biodegradable polymers have been getting more and more attention because of their contribution to the plastic pollution environmental issues and to move towards a circular economy. Nevertheless, biodegradable materials still exhibit various disadvantages restraining a widespread use in the market.
Paola Rizzarelli, Melania Leanza, Marco Rapisarda   +2 more
wiley   +1 more source

GFPT2 promotes paclitaxel resistance in epithelial ovarian cancer cells via activating NF-κB signaling pathway. [PDF]

Open Life Sci
Xu ZJ, Liu B, Li RN, Linghu H.
europepmc   +1 more source

Synthesis and Evaluation of Trehalose‐Based Mertansine Warheads for BCG Delivery of Anti‐Cancer Agents

ChemBioChem, Accepted Article.
Non‐muscle invasive bladder cancer (NMIBC) accounts for 75% of bladder cancer cases, with Bacillus Calmette‐Guérin (BCG) immunotherapy as the gold standard for high‐risk patients. BCG elicits a robust immune response but is limited by adverse effects and resistance. To enhance its efficacy, we developed a trehalose‐based conjugation strategy, tethering
Michael Grimmeisen, Xuan Wang, Melissa Weldle, Kerstin Sartory, Sara Benkhelifa, Yu Zhang, Trinh Dao, Jonas Meyer, Oliver Gorka, Olaf Groß, Claudia Jessen-Trefzer   +10 more
wiley   +1 more source

Comparison of nab-paclitaxel, paclitaxel, and oxaliplatin-induced peripheral neuro-pathy: a cross-sectional cohort study. [PDF]

Acta Oncol
Trinh T, Au K, Krishnan AV, Timmins HC, Li T, Grimison P, Goldstein D, Park SB.   +7 more
europepmc   +1 more source

Drug‐Coated Balloons Versus Non‐Coated Balloons for Side Branch Treatment in Bifurcation Lesions: A Systematic Review and Meta‐Analysis

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Coronary bifurcation lesions (CBL) account for ~20% of percutaneous coronary interventions (PCI). When using provisional stenting, optimal management of a diseased side branch (SB) remains debated. Drug‐coated balloons (DCBs) are an emerging option, but data on their role in CBL PCI are limited.
Matteo Rocchetti, Lorenzo Tua, Alberto Cereda, Barbara Conconi, A. Gabriele Franchina, Matteo Carlà, Andrea Spangaro, Stefano Lucreziotti   +7 more
wiley   +1 more source

Combining AdipoRon with Paclitaxel Unveils Synergistic Potential in Non-Small Cell Lung Cancer Cells via AMPK-ERK1/2 Signaling. [PDF]

Cells
Kafeel S, Palmiero G, Salzillo A, Ragone A, Naviglio S, Sapio L.   +5 more
europepmc   +1 more source

Paclitaxel‐Coated Balloons for Femoropopliteal Artery Disease Treatment in French Patients: A Longitudinal Observational Study

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Clinical studies have demonstrated the safety and effectiveness of drug‐coated balloon (DCB) angioplasty for femoropopliteal revascularization. Long‐term studies in routine practice are limited. Aims The aim of this study was to assess long‐term outcomes after DCB angioplasty for femoropopliteal peripheral artery disease in a real ...
Yann Gouëffic, Maxime Dubosq‐Lebaz, Jean‐François Heautot, Aurore Tricotel, Antoine Sauguet   +4 more
wiley   +1 more source

The First‐in‐Man Technique of Drug Eluting and Perfusion Therapy for Left Main Coronary Artery Disease

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Treating ostial left circumflex artery (LCx) lesions in percutaneous coronary intervention (PCI) for left main disease (LMD) remains a challenge. Despite recent recommendations for the use of drug‐coated balloon (DCB) in this lesion, there are concerns about crossover‐stenting from the left main trunk (LMT) to the left anterior ...
Takayuki Warisawa, Yoshiki Kawai, Takuya Matsumoto, Shingo Sato, Makoto Takeyama, Yuta Nakamura, Susumu Katsushika, Aritomo Katsura, Takahiro Sato, Masashiro Matsushita, Jiro Ando   +10 more
wiley   +1 more source

Omission of dexamethasone in paclitaxel premedication regimens: protocol of the multicentre, randomised, non-inferiority DEXASTOP trial. [PDF]

BMJ Open
Zietse M, Aalders LC, Spierings LEAMM, De Rouw N, Dercksen W, Dalm VASH, Oomen-de Hoop E, Thielen FW, Koch BCP, Mathijssen RHJ, van Doorn L, Leeuwen RWFV.   +11 more
europepmc   +1 more source

Targeted reactivation of the novel tumor suppressor DAPK1, an upstream regulator of p53, in high‐grade serous ovarian cancer by mRNA liposomes reduces viability and enhances drug sensitivity in preclinical models

Cancer Communications, EarlyView.
Monika Raab, Balázs Győrffy, Samuel Peña‐Llopis, Daniela Fietz, Monika Kressin, Margareta Kolaric, Matthias Ebert, Khayal Gasimli, Sven Becker, Mourad Sanhaji, Klaus Strebhardt   +10 more
wiley   +1 more source